Publisher： Adis International
ISSN： 0114-9954
Source： Reactions Weekly, Vol.1, Iss.1433, 2013-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
FDA review of Arcoxia and Prexige shows potential CV risk
Reactions Weekly, Vol. 1, Iss. 1038, 2005-01 ,pp. :
Access to resources
Recommend
FDA updates labelling for dronedarone with CV, death risk
Reactions Weekly, Vol. 1, Iss. 1383, 2012-01 ,pp. :
GnRH agonists: US FDA reviews CV safety
Reactions Weekly, Vol. 1, Iss. 1300, 2010-01 ,pp. :
US FDA announces ongoing assessment of CV risk for Stalevo
Reactions Weekly, Vol. 1, Iss. 1316, 2010-01 ,pp. :
Serious adverse CV events with varenicline
Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. :